Home Cart Sign in  
Chemical Structure| 155141-29-0 Chemical Structure| 155141-29-0

Structure of Rosiglitazone maleate
CAS No.: 155141-29-0

Chemical Structure| 155141-29-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Rosiglitazone maleate (BRL 49653C) is a potent and selective activator of PPARγ, with EC50 values of 30 nM, 100 nM, and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively, and a Kd of approximately 40 nM for PPARγ. It also modulates TRP channels by inhibiting TRP melastatin 2 (TRPM2) and TRPM3, and activating TRP canonical 5 (TRPC5).

Synonyms: BRL 49653C; Rosiglitazone (maleate); Avandaryl

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Rosiglitazone maleate

CAS No. :155141-29-0
Formula : C22H23N3O7S
M.W : 473.50
SMILES Code : O=C(SC1CC2=CC=C(C=C2)OCCN(C3=NC=CC=C3)C)NC1=O.O=C(/C=C\C(O)=O)O
Synonyms :
BRL 49653C; Rosiglitazone (maleate); Avandaryl
MDL No. :MFCD03427306

Safety of Rosiglitazone maleate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse mandibular mesenchymal stem cells (OMSCs) 1 μM 6 days Induced differentiation of OMSCs into adipocytes and detected lipid accumulation by oil red O staining. PMC7162802
3T3-L1 cells 1 μM Rosiglitazone upregulated HSPA12A expression in undifferentiated 3T3-L1 cells in a time-dependent manner. PMC6888823
Primary SVF cells 1 μM 6 days Rosiglitazone upregulated HSPA12A expression at the mRNA and protein levels in differentiated primary SVF cells. PMC6888823
Primary white adipocytes 1 μM 48 h Used to induce adipocyte differentiation and promote adipogenesis PMC7211001
Primary brown adipocytes 1 μM 2 days Used to induce brown adipocyte differentiation and promote adipogenesis PMC7211001
3T3-L1 preadipocytes 2 μM 3 days Induction of 3T3-L1 preadipocyte differentiation into adipocytes, results showed that Rosiglitazone induced AGMO expression and enzymatic activity during differentiation. PMC9192799
3T3-L1 cells 1 μM 36-48 h To investigate the effect of Rosiglitazone on TUSC5 protein levels, results showed that Rosiglitazone treatment significantly increased TUSC5 protein levels. PMC4632119
immortalized brown preadipocytes 1 nM 2 days To investigate the effect of Rosiglitazone on the differentiation of immortalized brown preadipocytes, results showed that Rosiglitazone treatment promoted differentiation into mature adipocytes. PMC4632119

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice High-fat diet-induced meibomian gland inflammation model Intraperitoneal injection 10 mg/kg Once daily for 4 weeks Rosiglitazone treatment significantly upregulated PPAR-γ gene and protein expression and reduced HFD-induced inflammatory cell infiltration and upregulation of pro-inflammatory cytokines. PMC8374999
Mice High-fat diet-induced obesity model Oral 10 mg/kg Once daily for 2 weeks To investigate the metabolic effects of Rosiglitazone in TUSC5 knockout and wild-type mice, results showed that Rosiglitazone significantly reduced fasting blood glucose and insulin levels in wild-type mice, but this effect was significantly blunted in TUSC5 knockout mice. PMC4632119
Mice Experimental dermal fibrosis model Oral gavage 5 mg/kg Once daily for 3 weeks To evaluate the preventive effect of Rosiglitazone on skin fibrosis, results showed that Rosiglitazone reduced collagen deposition and the number of α-SMA-positive myofibroblasts. PMC5136696
Mice High-fat diet-induced obese mouse model Dietary admixture 30 mg/kg Once daily for 15 days To investigate the effect of iNOS disruption on the metabolic actions of rosiglitazone, results showed that in obese mice lacking iNOS, rosiglitazone significantly improved glucose tolerance and liver insulin signaling, and increased plasma adiponectin levels. PMC2494686

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00306696 Diabetes Mellitus Phase 4 Completed - -
NCT00367055 Type 2 Diabetes Mellitus Phase 4 Completed - -
NCT00367055 - Completed - -
NCT00309309 Kidney Transplant Phase 2 Completed - Italy ... More >> Clinical Research Center for Rare Diseases Ranica, Bergamo, Italy, 24020 Less <<
NCT00314561 Metabolic Syndrome Phase 4 Completed - Korea, Republic of ... More >> Korea University Anam Hospital Seoul, Korea, Republic of, 136-705 Less <<
NCT00115661 Endometriosis Phase 2 Terminated(Due to the meta-ana... More >>lysis about CV adverse effects of rosiglitazone.) Less << - United States, Michigan ... More >> University of Michigan Health System Ann Arbor, Michigan, United States, 48109 Less <<
NCT00015691 HIV Infections ... More >> Lipodystrophy Hyperinsulinemia Less << Not Applicable Completed - -
NCT00131664 Type 2 Diabetes Mellitus Phase 3 Completed - Canada, Ontario ... More >> Canadian Heart Research Centre Toronto, Ontario, Canada, m5b 2p9 Less <<
NCT00364221 Metabolic Syndrome ... More >> Insulin Resistance Less << Phase 4 Completed - United States, Colorado ... More >> University of Colorado at Denver and Health Sciences Center General Clinical Research Center Denver, Colorado, United States, 80262 Less <<
NCT00522470 Type 2 Diabetes Mellitus ... More >> Obesity Less << Phase 4 Completed - Turkey ... More >> Baskent University Hospital Department of Endocrinology Ankara, Bahçelievler, Turkey, 06490 Less <<
NCT00452166 Chronic Kidney Disease ... More >> Insulin Resistance Less << Phase 3 Terminated(it was not possible... More >> to recruit new patients anymore) Less << - Netherlands ... More >> LUMC Leiden, Netherlands Less <<
NCT00123643 - Completed - -
NCT00123643 Type 2 Diabetes Mellitus Phase 4 Completed - United States, Minnesota ... More >> St. Paul Heart Clinic St. Paul, Minnesota, United States, 55102 Less <<
NCT00953498 Type 2 Diabetes Phase 4 Completed - France ... More >> Service Endocrinologie-diabétologie, Hôpital du Bocage CHU Dijon, France, 21000 Less <<
NCT00306644 Diabetes Mellitus, Type 2 Phase 4 Completed - Sweden ... More >> GSK Investigational Site Malmö, Sweden, SE-205 02 Less <<
NCT00131664 - Completed - -
NCT00130286 - Completed - -
NCT00618072 - Completed - -
NCT00492700 Non Alcoholic Steatohepatitis Phase 2 Completed - France ... More >> Service d'hépatogastroenérologie, Hôpital Pitié Salpêtrière Paris, France, 75013 Less <<
NCT00123227 Diabetes Mellitus, Type 2 ... More >> Vascular Diseases Hypertension Less << Phase 3 Unknown - United Kingdom ... More >> Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital London, United Kingdom, SW3 6NP St Mary's NHS Trust London, United Kingdom, W2 1NY Less <<
NCT00130286 HIV-Associated Lipodystrophy S... More >>yndrome Insulin Resistance HIV Infections Metabolic Syndrome X Body Weight Changes Less << Phase 1 Phase 2 Completed - United States, New York ... More >> AIDS Community Research Initiative of America (ACRIA) New York, New York, United States, 10018 Cornell HIV Clinical Trials Unit, Weill Medical College of Cornell University New York, New York, United States, 10021 St. Luke's-Roosevelt Hospital Center New York, New York, United States, 10025 Columbia University College of Physicians and Surgeons New York, New York, United States, 10032 Less <<
NCT00618072 Hyperinsulinemia ... More >> Insulin Resistance Obesity Less << Phase 2 Completed - United States, New York ... More >> Albert Einstein College of Medicine Bronx, New York, United States, 10461 Less <<
NCT00567593 Inflammatory Bowel Disease Phase 4 Completed - United States, Pennsylvania ... More >> University of Pennsylvania Clinical and Translational Research Center Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00501020 Diabetes Mellitus, Type 2 Phase 4 Completed - -
NCT00379769 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT00324675 Type 2 Diabetes ... More >> Overt Diabetic Nephropathy Less << Not Applicable Completed - Germany ... More >> University hospital Dresden Dresden, Germany, 01307 Less <<
NCT00324675 - Completed - -
NCT00348140 Alzheimer's Disease Phase 3 Completed - -
NCT00567593 - Completed - -
NCT00831129 Pre-diabetes Phase 2 Phase 3 Completed - United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less <<
NCT00831129 - Completed - -
NCT00285142 Healthy Not Applicable Completed - France ... More >> Centre d'Investigation Clinique Montpellier, France, 34295, cedex 5 Less <<
NCT00511823 Nausea and Vomiting, Chemother... More >>apy-Induced Less << Phase 1 Completed - United States, Indiana ... More >> GSK Investigational Site Evansville, Indiana, United States, 47714 Less <<
NCT00379769 - Completed - -
NCT00186537 - Completed - -
NCT01402076 Healthy Volunteers Phase 1 Completed - United States, Missouri ... More >> Bio-Kinetic Clinical Applications Springfield, Missouri, United States, 65802 Less <<
NCT00178841 Cutaneous T-cell Lymphoma ... More >> Mycosis Fungoides Sezary Syndrome Less << Phase 2 Completed - United States, Tennessee ... More >> Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232-5227 Less <<
NCT00178841 - Completed - -
NCT00348309 Alzheimer's Disease Not Applicable Completed - -
NCT00186537 Insulin Resistance ... More >> Hypertriglyceridemia Less << Not Applicable Completed - United States, California ... More >> Stanford University Medical Center Stanford, California, United States, 94305 Less <<
NCT00318656 Non-Insulin-Dependent Diabetes... More >> Mellitus Less << Phase 4 Completed - -
NCT00348140 - Completed - -
NCT00318656 - Completed - -
NCT00331487 Diabetes Mellitus Phase 3 Completed - -
NCT00675740 Impaired Glucose Tolerance Phase 4 Completed - -
NCT00116831 Atherosclerosis Phase 3 Completed - -
NCT00116831 - Completed - -
NCT00550420 Alzheimer's Disease Phase 3 Terminated(Based on preliminar... More >>y parent study results) Less << - -
NCT00348309 - Completed - -
NCT00490568 Alzheimer's Disease Phase 3 Terminated(Based on preliminar... More >>y parent study results) Less << - -
NCT01574820 Prediabetes C... More >>oronary Artery Disease Insulin Resistance Glucose Intolerance Less << Phase 3 Completed - -
NCT00490568 - Terminated(Based on preliminar... More >>y parent study results) Less << - -
NCT00098852 Head and Neck Cancer Phase 2 Unknown - United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 Less <<
NCT01332370 - Completed - -
NCT00550420 - Terminated(Based on preliminar... More >>y parent study results) Less << - -
NCT00688207 Alzheimer's Disease Phase 1 Completed - Germany ... More >> GSK Investigational Site Berlin, Germany, 10117 Less <<
NCT00279045 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT00428090 Alzheimer's Disease Phase 3 Completed - -
NCT00349427 Type 2 Diabetes Mellitus ... More >> Diabetes Mellitus, Type 2 Less << Phase 3 Completed - China, Jiangsu ... More >> GSK Investigational Site Nanjing, Jiangsu, China, 210008 China, Shanxi GSK Investigational Site Xian, Shanxi, China, 710032 China GSK Investigational Site Beijing, China, 100029 GSK Investigational Site Beijing, China, 100034 GSK Investigational Site Beijing, China, 100730 GSK Investigational Site Beijing, China, 100853 GSK Investigational Site Shanghai, China, 200001 GSK Investigational Site Shanghai, China, 200032 GSK Investigational Site Shanghai, China, 200233 GSK Investigational Site Tianjin, China, 300052 Less <<
NCT00194896 - Completed - -
NCT00194896 Type 2 Diabetes Mellitus Not Applicable Completed - United States, Washington ... More >> DVA Puget Sound Health Care System Seattle, Washington, United States, 98108 Less <<
NCT00306176 Type II Diabetes Mellitus Phase 4 Completed - Greece ... More >> AHEPA University Hospital of Thessaloniki Thessaloniki, Greece, 54454 Less <<
NCT00297063 Diabetes Mellitus, Type 2 Phase 3 Completed - Japan ... More >> GSK Investigational Site Hokkaido, Japan, 051-0005 GSK Investigational Site Ibaraki, Japan, 311-0113 GSK Investigational Site Kanagawa, Japan, 224-0024 GSK Investigational Site Tokyo, Japan, 125-0054 GSK Investigational Site Tokyo, Japan, 130-0004 Less <<
NCT00274495 Chronic Hepatitis C Infection ... More >> Fatty Liver Less << Phase 4 Terminated - United States, New York ... More >> Beth Israel Medical Center - Philipps Ambulatory Care Center New York, New York, United States, 10003 Less <<
NCT00290394 Diabetes Mellitus, Type 2 Phase 4 Completed - Turkey ... More >> Baskent University Ankara Hospital Ankara, Turkey, 06490 Less <<
NCT00119496 Asthma Phase 2 Phase 3 Completed - United Kingdom ... More >> Asthma Research Group, Gartnavel General Hospital Glasgow, Scotland, United Kingdom, G12 0YN Less <<
NCT00143624 Atherosclerosis ... More >> HIV Infections Less << Not Applicable Completed - Canada, British Columbia ... More >> St. Paul's Hospital Vancouver, British Columbia, Canada, V6Z 1Y6 Less <<
NCT00428090 - Completed - -
NCT01376063 Healthy Adult Subjects Phase 1 Completed - -
NCT00733174 Impaired Glucose Tolerance Phase 4 Unknown - United States, Colorado ... More >> South Federal Family Practice Recruiting Denver, Colorado, United States, 80219 Contact: Annette Grissett, MA    303-934-2202    annetteg@roydurbin.com    Contact: Stacey Mitchell, BSN, RN    303-399-8020 ext 2059    stacey.mitchell@va.gov Less <<
NCT00265148 Alzheimer's Disease Phase 2 Completed - United States, Arizona ... More >> GSK Investigational Site Litchfield Park, Arizona, United States, 85340 GSK Investigational Site Phoenix, Arizona, United States, 85006 GSK Investigational Site Scottsdale, Arizona, United States, 85259 GSK Investigational Site Sun City, Arizona, United States, 85351 GSK Investigational Site Tucson, Arizona, United States, 85724 United States, California GSK Investigational Site Los Angeles, California, United States, 90024 United States, Massachusetts GSK Investigational Site Belmont, Massachusetts, United States, 02478 United States, Michigan GSK Investigational Site Ann Arbor, Michigan, United States, 48109 United States, North Carolina GSK Investigational Site Durham, North Carolina, United States, 27705 Canada, Quebec GSK Investigational Site Montreal, Quebec, Canada, H3T 1E2 GSK Investigational Site Montreal, Quebec, Canada, H4H 1R3 United Kingdom GSK Investigational Site Liverpool, United Kingdom, L9 7LJ GSK Investigational Site Manchester, United Kingdom, M20 3LJ GSK Investigational Site Swindon, United Kingdom, SN1 4HZ GSK Investigational Site West End, Southampton, United Kingdom, SO30 3JB Less <<
NCT01453049 Diabetes Mellitus, Type 2 Phase 3 Terminated(US FDA/EMA/SFDA dec... More >>isions to rosiglitazone-containing medicines, ethic) Less << - China, Hubei ... More >> GSK Investigational Site Wuhan, Hubei, China, 430030 China, Jiangsu GSK Investigational Site Suzhou, Jiangsu, China, 215004 China, Liaoning GSK Investigational Site Dalian, Liaoning, China, 116027 China, Zhejiang GSK Investigational Site Hangzhou, Zhejiang, China, 310003 GSK Investigational Site Hangzhou, Zhejiang, China, 310009 China GSK Investigational Site Beijing, China, 100029 GSK Investigational Site Beijing, China, 100730 GSK Investigational Site Chongqing, China, 400016 GSK Investigational Site Shanghai, China, 200080 GSK Investigational Site Shenyang, China, 110003 GSK Investigational Site Tianjin, China, 300052 GSK Investigational Site Wuhan, China, 430022 Less <<
NCT01453049 - Terminated(US FDA/EMA/SFDA dec... More >>isions to rosiglitazone-containing medicines, ethic) Less << - -
NCT00135330 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, Arizona ... More >> Research Site Phoenix, Arizona, United States United States, California Research Site San Francisco, California, United States United States, Florida Research Site Jacksonville, Florida, United States Research Site Orlando, Florida, United States United States, Georgia Research Site Atlanta, Georgia, United States United States, Hawaii Research Site Honolulu, Hawaii, United States United States, Indiana Research Site Indianapolis, Indiana, United States United States, Massachusetts Research Site Boston, Massachusetts, United States Research Site Pittsfield, Massachusetts, United States United States, Minnesota Research Site Minneapolis, Minnesota, United States Research Site Rochester, Minnesota, United States United States, New York Research Site Bronx, New York, United States Research Site Syracuse, New York, United States United States, Ohio Research Site Cincinatti, Ohio, United States United States, Texas Research Site League City, Texas, United States Research Site New Braunfels, Texas, United States Research Site San Antonio, Texas, United States United States, Washington Research Site Renton, Washington, United States Research Site Spokane, Washington, United States Less <<
NCT00500955 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT00318630 Asthma Phase 1 Completed - New Zealand ... More >> GSK Investigational Site Wellington, New Zealand, 6035 Less <<
NCT01209143 Solid Cancers Phase 1 Completed - United States, California ... More >> Stanford, California, United States, 94305 United States, Michigan Detroit, Michigan, United States, 48201 United States, Texas Houston, Texas, United States, 77030 Less <<
NCT01415128 Erectile Dysfunction Phase 1 Completed - -
NCT00242619 Depression Bi... More >>polar Disorder Insulin Resistance Less << Not Applicable Completed - United States, California ... More >> Stanford University School of Medicine Stanford, California, United States, 94305 Less <<
NCT00135330 - Completed - -
NCT00242619 - Completed - -
NCT00413335 Obesity Impai... More >>red Glucose Tolerance Type 2 Diabetes Mellitus Less << Not Applicable Completed - United States, Connecticut ... More >> Yale School of Medicine New Haven, Connecticut, United States, 06520 Less <<
NCT00484419 Type 2 Diabetes ... More >> Hyperlipidemia Less << Phase 3 Completed - United States, California ... More >> La Mesa, California, United States Los Angeles, California, United States Los Gatos, California, United States San Antonio, California, United States United States, Florida Chiefland, Florida, United States United States, Indiana Gary, Indiana, United States United States, Maryland Baltimore, Maryland, United States United States, Michigan Dearborn, Michigan, United States W. Bloomfield, Michigan, United States United States, Nevada Las Vegas, Nevada, United States United States, New York Yonkers, New York, United States United States, North Carolina Lexington, North Carolina, United States Winston-Salem, North Carolina, United States United States, Ohio Munroe Falls, Ohio, United States Zaneville, Ohio, United States United States, Oregon Portland, Oregon, United States United States, Pennsylvania Jersey Shore, Pennsylvania, United States United States, South Carolina Clemson, South Carolina, United States United States, Tennessee Harriman, Tennessee, United States United States, Texas Dallas, Texas, United States Less <<
NCT00499707 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT01209143 - Completed - -
NCT00381238 Alzheimer's Disease Phase 2 Completed - United States, Arizona ... More >> GSK Investigational Site Litchfield Park, Arizona, United States, 85340 GSK Investigational Site Phoenix, Arizona, United States, 85006 GSK Investigational Site Sun City, Arizona, United States, 85351 United States, Massachusetts GSK Investigational Site Belmont, Massachusetts, United States, 02478 United States, Michigan GSK Investigational Site Ann Arbor, Michigan, United States, 48109 United States, North Carolina GSK Investigational Site Durham, North Carolina, United States, 27705 Canada, Quebec GSK Investigational Site Montreal, Quebec, Canada, H4H 1R3 Less <<
NCT00381238 - Completed - -
NCT01872780 Healthy Phase 1 Completed - -
NCT00285805 Insulin Resistance Not Applicable Completed - Netherlands ... More >> Radboud University Nijmegen medical centre Nijmegen, Netherlands, 6500 HB Less <<
NCT00484419 - Completed - -
NCT00614874 Asthma Phase 2 Completed - United States, Nebraska ... More >> Creighton University Medical Center, Department of Pulmonology and Critical Care Omaha, Nebraska, United States, 68131 Less <<
NCT00333723 Diabetes Mellitus, Type 2 Phase 4 Completed - -
NCT00614874 - Completed - -
NCT00612066 Cushing's Disease Phase 2 Terminated(Low accrual and fun... More >>ding term ended) Less << - United States, California ... More >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 Less <<
NCT01045590 Diabetes Mellitus, Type 2 Phase 4 Completed - Korea, Republic of ... More >> GSK Investigational Site Seoul, Korea, Republic of, 110-744 GSK Investigational Site Seoul, Korea, Republic of, 120-752 GSK Investigational Site Seoul, Korea, Republic of, 135-710 GSK Investigational Site Seoul, Korea, Republic of, 137-701 Less <<
NCT00612066 - Terminated(Low accrual and fun... More >>ding term ended) Less << - -
NCT00337350 Schizophrenia Phase 4 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Schizophrenia Program Boston, Massachusetts, United States, 02114 Less <<
NCT00432679 Diabetes Mellitus, Type 2 Phase 3 Completed - Japan ... More >> GSK Investigational Site Kumamoto, Japan, 862-0976 GSK Investigational Site Oita, Japan, 870-0039 Less <<
NCT00413335 - Completed - -
NCT00337350 - Completed - -
NCT01195259 - Completed - -
NCT00424762 - Completed - -
NCT00424762 Diabetes Mellitus, Type 2 Phase 4 Completed - United States, Texas ... More >> University of Texas Southwestern Medical Center Dallas, Texas, United States, 75390-9034 Less <<
NCT00231387 Non-insulin-dependent Diabetes... More >> Mellitus Less << Phase 3 Completed - United Kingdom ... More >> GSK Clinical Trials Call Center London, United Kingdom, W2 1NY Less <<
NCT03309319 Pituitary Tumor Not Applicable Recruiting December 31, 2018 China, Shanghai ... More >> Huashan Hospital Recruiting Shanghai, Shanghai, China, 200040 Contact: Min He, Doctor    +862152887027    mhe2004@263.net    Principal Investigator: Zhaoyun Zhang, Professor Less <<
NCT00367744 - Completed - -
NCT01406704 NASH (Non-alcoholic Steato-hep... More >>atitis) Less << Phase 4 Terminated(because of withdraw... More >>al of Avandia sale due to its risks outweigh its benefits) Less << December 2013 -
NCT01150981 Metabolic Syndrome ... More >> Insulin Resistance Less << Phase 2 Completed - United States, Massachusetts ... More >> UMass Medical School Worcester, Massachusetts, United States, 01655 Less <<
NCT00367744 HIV Infections Phase 2 Completed - United States, Ohio ... More >> Cleveland Clinc Foundation Cleveland, Ohio, United States, 44106 University Hospitals of Cleveland/Case Western Reserve University Cleveland, Ohio, United States, 44141 Less <<
NCT00004180 Sarcoma Phase 2 Completed - United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT00242593 Mild Cognitive Impairment Phase 2 Unknown December 2011 United States, Arizona ... More >> Banner Alzheimer Institute Phoenix, Arizona, United States, 85006 United States, California UCLA Alzheimer's Disease Center Los Angeles, California, United States, 90095 United States, Washington University of Washington/VA Puget Sound Health Care System Seattle/Tacoma, Washington, United States, 98108 Less <<
NCT01577095 Type 2 Diabetes Mellitus With ... More >>Features of Insulin Resistance Less << Phase 2 Completed - Taiwan ... More >> Department of Integrative Chinese-Western Clinic, China Medical University Hospital Taichung, Taiwan, 404 Less <<
NCT00819910 Hypertriglyceridemia in Type 4... More >> Hyperlipidemia Non Diabetic Subjects With Normoglycemia Less << Phase 4 Terminated(Slow recruitment an... More >>d increase in deployment overseas limiting follow up) Less << - United States, Texas ... More >> Brooke Army Medical Center San Antonio, Texas, United States, 78234 Less <<
NCT00819910 - Terminated(Slow recruitment an... More >>d increase in deployment overseas limiting follow up) Less << - -
NCT01150981 - Completed - -
NCT00746174 Insulin Sensitivity Phase 4 Completed - United States, Texas ... More >> University of Texas Southwestern Medical Center at Dallas Dallas, Texas, United States, 75390 Less <<
NCT00207402 Hepatitis C Phase 4 Completed - United States, Texas ... More >> Brooke Army Medical Center Ft. Sam Houston, Texas, United States, 78234 Less <<
NCT00609362 Change in Bone Mineral Density... More >> Change in Bone Marrow Fat Content Less << Phase 2 Completed - Denmark ... More >> Aarhus University Hospital Aarhus, Denmark, 8000 C Less <<
NCT00405015 Ischemia-Reperfusion Injury ... More >> The Metabolic Syndrome Less << Phase 2 Completed - Netherlands ... More >> Clinical research Center Nijmegen Nijmegen, Netherlands, 6500 HB Less <<
NCT00609362 - Completed - -
NCT00551564 Diabetes Mellitus, Type 2 Phase 1 Completed - United States, California ... More >> GSK Investigational Site Chula Vista, California, United States, 91911 Less <<
NCT00370305 Metabolic Syndrome ... More >> Impaired Glucose Tolerance Less << Phase 2 Completed - Germany ... More >> Charite, Campus Benjamin Franklin Berlin, Germany, 12200 Less <<
NCT00523913 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT02526615 Insulin Sensitivity ... More >> Type 2 Diabetes Less << Phase 4 Completed - Finland ... More >> Turku PET Centre Turku, Finland, 20520 Turku university hospital, PET center Turku, Finland, 20520 Turku PET Centre (Turku University Hospital) Turku, Finland, 20521 Less <<
NCT00169832 Diabetes Coro... More >>nary Artery Bypass Grafting Less << Phase 3 Completed - Canada, Nova Scotia ... More >> QEII Health Sciences Center - Halifax Infirmary Halifax, Nova Scotia, Canada, B3H 3A7 Canada, Ontario Hamilton Health Sciences - Mc Master Clinic Hamilton, Ontario, Canada, L8L 2X2 Toronto General Hospital Toronto, Ontario, Canada, M5G 2C4 Canada, Quebec CRMSBC Bonaventure, Quebec, Canada, G0C 1E0 CHUM Notre-Dame Hospital Montreal, Quebec, Canada, H2L 4M1 Laval Hospital Sainte-Foy, Quebec, Canada, G1V 4G5 Spain Hospital Del Mar Barcelona, Spain Hospital Universitari Vall D'Hebron Barcelona, Spain Hospital Universitarion Son Dureta Palma de Mallorca, Spain Less <<
NCT00486187 Type 2 Diabetes Mellitus Not Applicable Completed - Canada, Ontario ... More >> Partners Research Brampton, Ontario, Canada, L6V 1B4 Less <<
NCT00065065 - Completed - -
NCT00182052 Adenocarcinoma of the Prostate... More >> Prostate Cancer Less << Phase 3 Completed - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT00616642 Brain and Central Nervous Syst... More >>em Tumors Less << Phase 2 Terminated(low patient recruit... More >>ment) Less << - United States, California ... More >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 Less <<
NCT02694874 Malaria Not Applicable Recruiting December 2019 Mozambique ... More >> Centro de Investigação em Saude da Manhiça Recruiting Manhiça, Maputo, Mozambique, CP1929 Contact: Quique Bassat, PhD          Contact: Eusebio Macete, PhD Less <<
NCT00065065 Ulcerative Colitis ... More >> Inflammatory Bowel Disease Less << Phase 2 Completed - United States, Georgia ... More >> Atlanta Gastroenterology Associates Atlanta, Georgia, United States, 30342 United States, Illinois University of Chicago Hospitals Chicago, Illinois, United States, 60637 United States, Maryland Metropolitan Gastroenterology Group Practice/Chevy Chase Clinical Research Chevy Chase, Maryland, United States, 20815 Maryland Digestive Diseases Research Laurel, Maryland, United States, 20707 Capitol Gastroenterology Consultants Silver Spring, Maryland, United States, 20901 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 United States, Minnesota Minnesota Gastroenterology Plymouth, Minnesota, United States, 55446 United States, New Jersey Atlantic Gastroenterology Associates Egg Harbor Township, New Jersey, United States, 08234 United States, North Carolina Wake Research Associates Raleigh, North Carolina, United States, 27612 United States, Ohio University Hospitals of Cleveland Cleveland, Ohio, United States, 44106 The Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Avamar Center for Endoscopy Warren, Ohio, United States, 44484 United States, Pennsylvania University of Pennsylvania - Presbyterian Medical Center Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00785213 Healthy Phase 1 Completed - United States, Minnesota ... More >> Cetero Research East Grand Forks, Minnesota, United States, 56721 Less <<
NCT00369174 Oral Leukoplakia Phase 2 Completed - United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01706211 Diabetes Mellitus Non Insulin ... More >>Dependent Oral Agent Therapy Less << Phase 3 Completed - Taiwan ... More >> National Taiwan University Hospital Taipei, Taiwan, 10002 Less <<
NCT00785213 - Completed - -
NCT00616642 - Terminated(low patient recruit... More >>ment) Less << - -
NCT01100619 Papillary Thyroid Cancer ... More >> Follicular Thyroid Cancer Huerthle Cell Thyroid Cancer Renal Cell Carcinoma Less << Phase 1 Completed - United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Montefiore Medical Center Bronx, New York, United States, 10466 United States, Pennsylvania Hospital of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 United States, Texas The University of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77230 Less <<
NCT03492580 - Completed - United States, New Jersey ... More >> Janssen Investigative Site Titusville, New Jersey, United States, 08560 Less <<
NCT00975286 Type 2 Diabetes Mellitus Phase 3 Completed - -
NCT02476760 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT02456428 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT00975286 - Completed - -
NCT00000620 - Completed - -
NCT02475499 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT00885352 Type 2 Diabetes Mellitus Phase 3 Completed - -
NCT00000620 Atherosclerosis ... More >> Cardiovascular Diseases Hypercholesterolemia Hypertension Diabetes Mellitus, Type 2 Diabetes Mellitus Coronary Disease Less << Phase 3 Completed - United States, Minnesota ... More >> Minneapolis Medical Research Foundation Minneapolis, Minnesota, United States, 55404 United States, New York Columbia University New York, New York, United States, 10027 United States, North Carolina Wake Forest University Winston-Salem, North Carolina, United States, 27106 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 United States, Tennessee Veterans Affairs Memphis, Tennessee, United States, 38104 United States, Washington University of Washington Seattle, Washington, United States, 98195 Canada, Ontario McMaster University Hamilton, Ontario, Canada Less <<
NCT00885352 - Completed - -
NCT00814255 Focal Segmental Glomeruloscler... More >>osis Less << Phase 2 Completed - United States, Florida ... More >> University of Miami Miami, Florida, United States, 33136 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Kansas University of Kansas Kansas City, Kansas, United States, 66160 United States, Massachusetts Boston Children's Hospital Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55901 United States, Missouri Children's Mercy Hospital Kansas City, Missouri, United States, 64108 Cardinal Glennon Children's Medical Center Saint Louis, Missouri, United States, 63104 United States, New York Steven and Alexandra Cohen Children's Medical Center of New York New Hyde Park, New York, United States, 11040 NYU Langone Medical Center New York, New York, United States, 10016 Columbia University Medical Center New York, New York, United States, 10032 United States, North Carolina Carolinas Medical Center Charlotte, North Carolina, United States, 28207 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 Ohio State University Columbus, Ohio, United States, 43205 United States, Oregon Doernbecher Children's Hospital Portland, Oregon, United States, 97239 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas Texas Tech University El Paso, Texas, United States, 79905 Canada, Alberta University of Alberta Edmonton, Alberta, Canada, T6G 2R7 Less <<
NCT00950534 Diabetes Mellitus, Type 2 Phase 4 Terminated(due to poor recruit... More >>ment) Less << - Australia ... More >> Sanofi-Aventis Administrative Office Macquarie Park, Australia Less <<
NCT00814255 - Completed - -
NCT00964106 Drug Interactions Phase 1 Completed - Korea, Republic of ... More >> GSK Investigational Site Busan, Korea, Republic of, 614-735 GSK Investigational Site Seoul, Korea, Republic of, 110-744 Less <<
NCT00732121 Type 2 Diabetes Phase 4 Unknown August 2010 United States, Vermont ... More >> University of Vermont South Burlington, Vermont, United States, 05403 Less <<
NCT00376870 Coronary Atherosclerosis ... More >> Coronary Restenosis Diabetes Less << Phase 3 Unknown April 2011 Italy ... More >> Policlinico di Tor Vergata Not yet recruiting Rome, Italy, 00133 Principal Investigator: Fabrizio Clementi, MD. PhD          Policlinico di Tor Vergata Recruiting Rome, Italy, 00133 Contact: Saverio Muscoli, MD    +390620904009    fabrizio.clementi@me.com    Principal Investigator: Fabrizio Clementi, MD, PhD Less <<
NCT01175486 Diabetes Phase 4 Unknown December 2015 Taiwan ... More >> Taipei Veterans General Hospital, Taiwan Recruiting Taipei, Taiwan Principal Investigator: Harn-Shen Chen, MD, PhD Less <<
NCT00481663 Type II Diabetes Mellitus Phase 2 Completed - -
NCT00341406 - Completed - United States, Maryland ... More >> National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK), 9000 Bethesda, Maryland, United States, 20892 Less <<
NCT01408862 - Completed - -
NCT02341703 Polycystic Ovary Syndrome ... More >> Infertility Less << Early Phase 1 Completed - Egypt ... More >> faculty of medicine, Cairo University Cairo, Egypt, 002 Less <<
NCT00467285 - Completed - -
NCT01909141 Polycystic Ovary Syndrome ... More >> Infertility Less << Early Phase 1 Completed - Egypt ... More >> Cairo University Cairo, Egypt Less <<
NCT00467285 - Completed - -
NCT01408862 - Completed - -
NCT02285205 Type 2 Diabetes ... More >> Non-alcoholic Fatty Liver Disease Less << Phase 4 Completed - Korea, Republic of ... More >> Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine Seoul, Korea, Republic of, 120-752 Less <<
NCT00099853 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00138554 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT01909141 - Completed - -
NCT00357370 Type 2 Diabetes Phase 2 Phase 3 Completed - -
NCT00015626 Insulin Resistance ... More >> Diabetes Mellitus Less << Phase 2 Completed - United States, New York ... More >> Cornell University New York, New York, United States, 10021 Less <<
NCT00357370 - Completed - -
NCT00364988 Type 2 Diabetes ... More >> Diabetic Nephropathy Less << Not Applicable Completed - -
NCT00386100 Diabetes Mellitus, Type 2 Phase 4 Completed - -
NCT00926016 Chronic Hepatitis C Not Applicable Completed - United States, Texas ... More >> Brooke Army Medical Center San Antonio, Texas, United States, 78234 Less <<
NCT00386100 - Completed - -
NCT00293137 - Terminated(safety concerns reg... More >>arding use of rosiglitazone) Less << - United States, Ohio ... More >> Cleveland Clinic Cleveland, Ohio, United States, 44195 Less <<
NCT00295633 Diabetes Mellitus, Type 2 Phase 3 Completed - -
NCT00396227 Diabetes Mellitus, Type 2 Phase 3 Completed - United States, New Jersey ... More >> Novartis Pharmaceuticals East Hanover, New Jersey, United States, 07936 Less <<
NCT00745914 Endstage Renal Disease ... More >> Diabetes Less << Not Applicable Completed - Hong Kong ... More >> Queen Mary Hospital and Tung Wah Hospital Hong Kong, Hong Kong, 0000 Queen Mary Hospital, Tung Wah Hospital Hong Kong, Hong Kong, 0000 Less <<
NCT01055223 - Completed - -
NCT00295633 - Completed - -
NCT01055223 - Completed - -
NCT00680745 Type 2 Diabetes Phase 3 Completed - -
NCT00636766 Carotid Atherosclerosis ... More >> Stroke Type 2 Diabetes Metabolic Syndrome Less << Not Applicable Completed - Greece ... More >> General Hospital of Thessaloniki "Hippokratio" Thessaloniki, Greece Less <<
NCT00232362 Type 2 Diabetes Mellitus Phase 1 Withdrawn(This study was not c... More >>onducted as the Principal Investigator left the institution) Less << June 2008 -
NCT00680745 - Completed - -
NCT00437970 Diabetes Mellitus, Type 2 Phase 4 Withdrawn(Unable to secure sup... More >>ply of the study medication) Less << February 2009 Australia, Northern Territory ... More >> Menzies School of Health Research Darwin, Northern Territory, Australia, 0810 Less <<
NCT00776607 Latent Autoimmune Diabetes in ... More >>Adults LADA Less << Not Applicable Unknown April 2011 United Kingdom ... More >> Diabetes Unit Not yet recruiting Cardiff, Wales, United Kingdom, CF64 2XX Contact: Julia Platts    02920 711 711 ext 5149    Julia.Platts@CardiffandVale.wales.nhs.uk    Principal Investigator: Julia Platts          Clinical Research Unit Recruiting Swansea, Wales, United Kingdom, SA6 6NL Contact: Lucy Barlow    +44 (0) 1792 703722 ext 3722    Lucy.Barlow@swansea-tr.wales.nhs.uk    Principal Investigator: Jeffrey Stephens Less <<
NCT00692510 Metabolism Al... More >>zheimer's Disease Less << Phase 1 Completed - Sweden ... More >> Research Site Uppsala, Sweden Less <<
NCT00443170 Healthy Subjects ... More >> Anaemia Less << Phase 1 Completed - Australia, New South Wales ... More >> GSK Investigational Site Randwick, Sydney, New South Wales, Australia, 2031 Australia, Queensland GSK Investigational Site Herston, Queensland, Australia, 4006 Australia, South Australia GSK Investigational Site Adelaide, South Australia, Australia, 5000 Less <<
NCT02737709 Non-small Cell Lung Cancer Phase 2 Terminated(The study have diff... More >>iculty in recruiting subjectes) Less << - China, Guangdong ... More >> Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China, 510060 Less <<
NCT00359112 Non-Insulin-Dependent Diabetes... More >> Mellitus Less << Phase 3 Completed - -
NCT00742326 - Terminated(Enrollment stopped ... More >>prior to complete enrollment due to slow accrual) Less << - -
NCT00742326 HIV Hepatitis... More >> C Liver Disease Fatty Liver Steatosis Less << Phase 4 Terminated(Enrollment stopped ... More >>prior to complete enrollment due to slow accrual) Less << - United States, District of Col... More >>umbia VA Medical Center Washington, District of Columbia, United States, 20422 United States, Maryland National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00197132 Insulin Resistance PHASE3 COMPLETED 2025-08-03 GSK Clinical Trials Call Cente... More >>r, Nijmegen, 6525EZ, Netherlands Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.56mL

2.11mL

1.06mL

21.12mL

4.22mL

2.11mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories